Hope for Patients with NASH

http://youtu.be/nEB5cQYFJPs Approximately 30% of adults in the U.S. have fatty liver, and 15% of them will progress to having nonalcoholic steatohepatitis (NASH). At Pfizer, we’re striving to use our expertise in metabolic disorders to develop treatments that have the potential to significantly improve the lives of patients with NASH. Hope for Patients with NASH